Lipocine
LPCN
45 hedge funds and large institutions have $16.6M invested in Lipocine in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 10 closing their positions.
6,400% more call options, than puts
Call options by funds: $65K | Put options by funds: $1K
298% more capital invested
Capital invested by funds: $4.16M → $16.6M (+$12.4M)
0.03% less ownership
Funds ownership: 0.7% → 0.67% (-0.03%)
8% less funds holding
Funds holding: 49 → 45 (-4)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| 1 |
Millennium Management
New York
|
+$55.7K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.1K |
| 3 |
CA
Carson Advisory
Athens,
Georgia
|
+$23.6K |
| 4 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$18.3K |
| 5 |
Jane Street
New York
|
+$11.1K |
Top Sellers
| 1 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$192K |
| 2 |
Mercer Global Advisors
Denver,
Colorado
|
-$63K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$33.2K |
| 4 |
B
Bailard
Foster City,
California
|
-$31.9K |
| 5 |
Two Sigma Investments
New York
|
-$16K |
LPCN Hedge Fund Activity: Q1 2023 in Review
45 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2023, worth a combined $16.6M — up 298% from $4.16M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LPCN and 6 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, adding an estimated $55.7K. The largest seller was Wealth Effects, cutting an estimated $192K.
- 45 institutional investors held Lipocine (LPCN) as of Q1 2023, down from 49 in Q4 2022.
- Funds reported $16.6M of Lipocine stock for Q1 2023, up 298% quarter-over-quarter.
- 6 funds opened new Lipocine positions in Q1 2023 and 10 closed out, a net change of -4 holders.
- The largest Lipocine buyer in Q1 2023 was Millennium Management, an estimated $55.7K added.
- The largest Lipocine seller in Q1 2023 was Wealth Effects, an estimated $192K sold.
Based on aggregated 13F filings for Q1 2023.